Windy City Media Group Frontpage News

THE VOICE OF CHICAGO'S GAY, LESBIAN, BI, TRANS AND QUEER COMMUNITY SINCE 1985

home search facebook twitter join
Gay News Sponsor Pre-order Book!
Pre-order Book!
Donate

Sponsor
Sponsor

  WINDY CITY TIMES

PrEP options likely to change following Truvada patent expiration
by Matt Simonette
2021-03-04

This article shared 776 times since Thu Mar 4, 2021
facebook twitter pin it google +1 reddit email


Among the myriad challenges facing HIV/AIDS advocates and healthcare providers has been increasing use of pre-exposure prophylaxis, or PrEP, among persons at risk for HIV transmission. A PrEP intervention, which usually consists of taking the oral medication Truvada, has been shown to decrease the risk of transmission by more than 90 percent.

Truvada was approved for PrEP use by the Food and Drug Administration in 2012 and, since then, has been widely prescribed by physicians to help at-risk patients prevent HIV transmission (it was earlier used to treat persons living with HIV). But Truvada's patent expiration in 2020 means both generic options for consumers are forthcoming and that a competing drug, Descovy, by the same manufacturer, is already on the market.

Some advocates are looking forward to having lower-cost options available. AIDS Foundation of Chicago (AFC) Senior Director of Prevention Advocacy and Gay Men's Health Jim Pickett suspects that "lower drug costs will lower the cost of access and alleviate some pressure on the system."

He added, "With PrEP, the costs are not just about the drug. There are costs affiliated with seeing your doctor, having blood work done, being tested for HIV and STI's. It's important to remember that services that come along with PrEP are part of the program—PrEP isn't just a prescription. If our system can spend less on the drug, there's arguably more money to cover those other things which can be prohibitive for people."

The cost of Truvada—which is a combination of the drugs known generically as tenofovir disoproxil fumarate and emtricitabine—has indeed been a key deterrent to widespread PrEP implementation. A month's supply of the medication is often $1,500-2,000. Nevertheless, many insurers cover Truvada in their formularies, and the medication's manufacturer, Foster City, California-based Gilead Sciences, provides consumer assistance for monthly co-payments their plans require.

Various public health agencies have also made PrEP access a central component to long-term strategies that eliminate new HIV transmissions, such as the Getting to Zero initiative launched in Illinois in late 2018. The federal government announced a similar program with PrEP interventions playing a central role in early 2019.

Nevertheless, PrEP adoption numbers remain far behind where advocates and providers want to see them. Getting the message about PrEP to white gay men has been a relatively minimal challenge, but communicating that same message to diverse audiences at risk, such as transgender women or young Black men, remains problematic. Usage in the southern United States, where a large number of new HIV transmissions take place, is also low.

In late 2019, Gilead announced it would donate a five-year supply of Truvada to 200,000 people. Their Truvada patent expired in late 2020. The company reached an exclusivity agreement for six months Israeli pharmaceutical manufacturer Teva for a generic version of tenofovir disoproxil fumarate and emtricitabine. Starting in spring 2021, Teva's exclusivity window expires and any manufacturer can produce a generic version of tenofovir disoproxil fumarate and emtricitabine.

Gilead still intends to remain a player in manufacturing and distributing medications for PrEP, however. In 2019, it received approval for use of Descovy as a PrEP intervention and has aggressively marketed the new drug as a replacement for Truvada. Google users who search "Truvada generic" will likely spot an advertisement for Descovy toward the top of their results.

Among the advantages of Descovy, according to Gilead, are reduced chances of complications to kidneys or bone density, which are stated side-effects to Truvada. But Descovy shares the same high cost as Truvada, about $16,600-20,000 a year, according to aidsmap.com .

Many advocates and providers say that there is no need for a "mass exodus" from Truvada to Descovy for PrEP users, Pickett said.

"In terms of prescribing for PrEP, the vast majority of people using Truvada for PrEP have absolutely zero clinical need to switch over to Descovy," he added. "The only clinical reason to switch would be if you have some underlying kidney or bone disease, or if Truvada is giving your kidneys a hard time."

Gilead could not provide a spokesperson to comment on Descovy by this article's deadline. Shortly after Descovy was approved for PrEP in October 2019, Daniel O'Day, Gilead's chairman and CEO, said the new medication nevertheless "provides a new HIV prevention option that matches Truvada's high efficacy with statistically significant improvements in renal and bone safety, which can be an important consideration as people at risk increasingly use PrEP for longer periods of time."

Prior to her appointment as director of the Centers for Disease Control and Prevention, Rochelle Walensky, MD, was lead author on a March 2020 Annals of Internal Medicine study which concluded that mitigating for Truvada's side-effects with a new medication was outweighed by the benefits of a lower-cost generic substitute for Truvada. Other researchers also have expressed concern that Descovy has not been tested on as diverse a population as Truvada has been.

"We already are seeing insurance companies pointing people to the generic alternative—when you are prescribed PrEP, the insurance company might cover the generic form of Truvada," Pickett said. "They may or may not be inclined to cover Truvada itself. We are also seeing insurance companies put in utilization-management for Descovy, so if you are prescribed Descovy, the doctor has to show clinical need."

Gilead has also been involved in extensive litigation with the federal government regarding the PrEP-related patents. The CDC sued the company in 2019, maintaining that it had not been properly compensated for federal researchers' contributions to Truvada and Descovy's development. In January 2021, a federal judge rejected the Justice Department's motion to dismiss Gilead's counterclaims that the federal government had been in breach of key contracts, so the litigation will continue.

But for now, a key challenge for stakeholders remains getting the costs under control. Using PrEP represents a collective commitment of time and money for patients, providers and insurers.

In the years ahead, the PrEP landscape will likely change even further. An injectable version of the intervention has proven to be as effective as oral applications. In such a scenario, the medication cabotegravir could be injected and offer two months' worth of protection for patients who don't wish to take a pill every day.

Pickett said he didn't foresee injectable PrEP completely replacing pills however, noting that compliance challenges might only shift for some consumers. While the injection saves the patient from the responsibility of taking a pill, they'd still need a bimonthly appointment to receive it.

"I don't see it as replacing [oral medication]—I see it as being additive," Pickett said. "I see it drawing in people who struggle with PrEP because it is a pill, or aren't interested because it's a pill. Overall, if we do it right and create support systems that make it easy for people to get their shots—imagine being able to do it at Walgreens—I'll be super-excited about it. It means people having more options and more protection."


This article shared 776 times since Thu Mar 4, 2021
facebook twitter pin it google +1 reddit email





Windy City Media Group does not approve or necessarily agree with the views posted below.
Please do not post letters to the editor here. Please also be civil in your dialogue.
If you need to be mean, just know that the longer you stay on this page, the more you help us.


  ARTICLES YOU MIGHT LIKE

Gay News

Decriminalization of HIV approved in Judiciary-Criminal Committee 2021-04-14
--From a Illinois HIV Action Alliance press release - SPRINGFIELD — Today, the Illinois House Judiciary-Criminal Committee voted 18-0 to approve House Bill 1063 HA1, which would end criminal penalties against people living with HIV (PLWH). Under current law, PLWH face the threat of arrest, ...


Gay News

HIV/AIDS Report: Vaccine may hold promise 2021-04-10
- Preliminary data from an early stage clinical trial out of the International AIDS Vaccine Initiative (IAVI) and The Scripps Research Institute in La Jolla, California, suggests that a new HIV vaccine may hold promise, ABC News ...


Gay News

AIDS Healthcare Foundation Lake View clinic holds ribbon-cutting 2021-04-03
- Los Angeles-based AIDS Healthcare Foundation (AHF) held a ribbon-cutting event for its Lake View facility on March 31. The clinic, 3311 N. Halsted St., is housed within AHF's Out of the Closet thrift store and will ...


Gay News

NATIONAL Anti-trans attacks, Native HIV/AIDS Awareness Day, tower, Mary Trump 2021-03-28
- Rayanna Pardo, a 26-year-old Latinx trans woman, was struck by a car and killed while fleeing from a small mob in Los Angeles on March 17, out.com reported. Security video showed Pardo being chased and assaulted ...


Gay News

PASSAGES Roman Buenrostro 2021-03-26
- Roman Buenrostro, a past AIDS Foundation Chicago (AFC) Director of Special Projects passed away on March 25, 2021. He was a longtime LGBTQ+ leader and activist for people living with HIV and a co-founder of the ...


Gay News

Season of Concern benefit with Dixie Longate through March 28 2021-03-22
- Dixie Longate—the fast-talking, gum chewing, ginger-haired Alabama drag personality—is headlining Dixie's Happy Hour as a benefit for Season of Concern Chicago. People are urged to spend an evening with Dixie ...


Gay News

Elton John AIDS Foundation Oscars party to be virtual on April 25 2021-03-22
- The 29th annual Elton John AIDS Foundation (EJAF) Academy Awards Pre-Party will be hosted by Emmy- and Tony-winning actor and New York Times best-selling author Neil Patrick Harris alongside Sir Elton John and David Furnish, with ...


Gay News

Chicago House, Center on Halsted among recipients of DIFFA/Chicago funding awards 2021-03-20
--From a press release - (Chicago) — DIFFA/Chicago (Design Industries Foundation Fighting AIDS/Chicago) is pleased to announce the recipients of this year's Excellence in Care Awards. DIFFA/Chicago's Board of Directors tasked its Grants Committee to ...


Gay News

AFC holds virtual annual meeting, awards ceremony: Innovation Through Action 2021-03-09
- AIDS Foundation Chicago (AFC) held its annual meeting and awards ceremony, "Innovation Through Action," March 4 via Zoom. (It was virtual due to the ongoing COVID-19 pandemic.) AFC President/CEO John Peller said that although much has ...


Gay News

Racial justice coalition urges prosecutor to drop Jussie Smollett charges 2021-03-04
--From a press release - CHICAGO — Today, a coalition of racial justice and faith based organizations led by the National Black Justice Coalition and including Black Gifted and Whole, National Center for Lesbian Rights, Community Renewal Society, Black AIDS Institute, ...


Gay News

SPECIAL ISSUE: AIDS at 40 2021-03-04
- In this special quarterly issue, produced by Windy City Timesas as an insert to the Chicago Reader, Windy City Times speaks with long-term HIV/AIDS survivors, deals with HIV-positive representation in media, checks in on young activists of today ...


Gay News

TANIA UNZUETA: Fighting for justice, one cause at a time 2021-03-04
- LGBTQ, immigration and political activist Tania Unzueta has spent the last three years living in Georgia involved in political and electoral organizing. She returned to Chicago in January with her partner. Unzueta came to Chicago from ...


Gay News

HIV at 40: Long-term AIDS survivor Sean Strub on diagnosis, being mayor, Larry Kramer 2021-03-04
- To say Sean Strub is a fighter is almost the supreme understatement. He was diagnosed with HIV/AIDS in the mid-1980s—when having the disease was almost certainly a death sentence. (Even the doctor who diagnosed him passed ...


Gay News

STILL HERE: Long-term HIV/AIDS survivors in Chicago reflect on their experiences 2021-03-04
- When the first reported U.S. cases of what later became known as HIV/AIDS were reported in June 1981, a number of physicians and researchers at the Centers for Disease Control (CDC) and elsewhere sought to understand ...


Gay News

One-third of gay, bisexual men who take PrEP discontinue within three years 2021-02-25
--From a press release - Familiarity and favorable attitudes towards PrEP have increased over time, though use remains low A new study from the Williams Institute at UCLA School of Law finds a significant increase in familiarity with pre-exposure prophylaxis (PrEP) ...


 



Copyright © 2021 Windy City Media Group. All rights reserved.
Reprint by permission only. PDFs for back issues are downloadable from
our online archives. Single copies of back issues in print form are
available for $4 per issue, older than one month for $6 if available,
by check to the mailing address listed below.

Return postage must accompany all manuscripts, drawings, and
photographs submitted if they are to be returned, and no
responsibility may be assumed for unsolicited materials.
All rights to letters, art and photos sent to Nightspots
(Chicago GLBT Nightlife News) and Windy City Times (a Chicago
Gay and Lesbian News and Feature Publication) will be treated
as unconditionally assigned for publication purposes and as such,
subject to editing and comment. The opinions expressed by the
columnists, cartoonists, letter writers, and commentators are
their own and do not necessarily reflect the position of Nightspots
(Chicago GLBT Nightlife News) and Windy City Times (a Chicago Gay,
Lesbian, Bisexual and Transegender News and Feature Publication).

The appearance of a name, image or photo of a person or group in
Nightspots (Chicago GLBT Nightlife News) and Windy City Times
(a Chicago Gay, Lesbian, Bisexual and Transgender News and Feature
Publication) does not indicate the sexual orientation of such
individuals or groups. While we encourage readers to support the
advertisers who make this newspaper possible, Nightspots (Chicago
GLBT Nightlife News) and Windy City Times (a Chicago Gay, Lesbian
News and Feature Publication) cannot accept responsibility for
any advertising claims or promotions.

 

 

 

TRENDINGBREAKINGPHOTOS







Sponsor
Sponsor


 



Donate


About WCMG      Contact Us      Online Front  Page      Windy City  Times      Nightspots      OUT! Guide     
Identity      BLACKlines      En La Vida      Archives      Advanced Search     
Windy City Queercast      Queercast Archives     
Press  Releases      Join WCMG  Email List      Email Blast      Blogs     
Upcoming Events      Todays Events      Ongoing Events      Bar Guide      Community Groups      In Memoriam      Outguide Categories      Outguide Advertisers      Search Outguide      Travel      Dining Out      Privacy Policy     

Windy City Media Group publishes Windy City Times,
The Bi-Weekly Voice of the Gay, Lesbian, Bisexual and Trans Community.
5315 N. Clark St. #192, Chicago, IL 60640-2113 • PH (773) 871-7610 • FAX (773) 871-7609.